Making dreams a reality Endless challenges and success A new future to come

Launched in 2018, the KOLON Institute of Technology has created new value and broke down boundaries to discover future growth engines as an R&D control tower. We are preparing for a new leap forward through R&D and synergy between our subsidiaries to develop new technologies and expand business portfolios to prepare future growth engines for our group.

KOLON Institute of Technology serves as a hub for convergence R&D to realize KOLON’s future values. We focus on ESG-driven R&D to lead sustainable growth for our group. We continue to explore and promote new business opportunities by establishing a network with global leaders. KOLON Institute of Technology aims to develop a creative and flexible community of experts to discover new technology pipelines and create new business opportunities. To achieve this goal, we are nurturing groups of technical experts in various new fields and strengthening the efficiency of staff operations.

In 1978, KOLON INDUSTRIES R&D Headquarters was the first research center founded in the Korean chemical fiber industry. Since then, we have been providing technology platforms as a core technological competitiveness for material development to lead the growth of KOLON INDUSTRIES.

Our portfolio includes Film, Electronic & Display Materials, High-Performance Industrial Materials, Automotive Materials, Green & Energy Materials, and Chemicals. Based on our creative and challenging research culture, we are committed to strengthening the competitiveness of our current business through material development and applied technology and striving to build an R&D network to lay a foundation for new businesses in the future.

KOLON GLOTECH R&D Headquarters is focusing on R&D to strengthen the competitiveness of our current businesses and discover new business opportunities with the vision of becoming a Smart interior solution creator.

Our R&D strategy focuses on:

KOLON LIFE SCIENCE BIO Research Center is committed to developing innovative cell and gene therapies based on our vision of becoming a Global Leading Cell & Gene Therapy Company.

To become a global leader in cell and gene therapy, our BIO Research Center focuses on treating neurological disorders and cancer and developing innovative viral carrier-based gene therapies. Subsequent pipelines include treatment for neuropathic pain, KLS-2031 (Phase 1/2a clinical trial in the US), and oncolytic viral therapy, KLS-3021 (preclinical study). We will continue to upgrade our viral carrier platform technology and reinforce our portfolio to secure differentiated capabilities in developing innovative gene therapies.

KOLON LIFE SCIENCE Chemical Research Center will become a leader in APIs and fine chemistry by developing various APIs, intermediates for pharmaceuticals, and antibacterial agents based on our rich experience in synthesis and convergence technologies.

Our Chemical Research Center develops APIs, fine chemicals, and water treatment products. We have successfully entered the Japanese pharmaceutical market by securing a diverse portfolio of APIs and intermediates for pharmaceuticals. We are also growing into a specialized CMO/CDMO company by supplying new clinical drugs and intermediates. Based on the differentiated technologies of our research center, KOLON LIFE SCIENCE is building a competitive process infrastructure, such as catalyst-based process and continuous process development, and supplying antibacterial agents and advanced electrical/electronic materials to domestic and global companies.